Coagulation measures after cardiac arrest (CMACA)

Hyo Joon Kim; Kurz Michael; Jung Hee Wee; Joo Suk Oh; Won Young Kim; In Soo Cho; Mi Jin Lee; Dong Hun Lee; Yong Hwan Kim; Chun Song Youn

doi:10.1371/journal.pone.0279653

Peer Review History

Original SubmissionMay 8, 2022
27 Oct 2022 Decision Letter - Chiara Lazzeri, Editor PONE-D-22-13494Coagulation measures after cardiac arrest (CMACA)PLOS ONE Dear Dr. Youn, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. we suggest the Authors to add a paragraph summarizing the main findings focusing on the clinical view. Please submit your revised manuscript by Dec 08 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Chiara Lazzeri Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. Please provide the names of each of the institutional review boards which approved this study. 3. Thank you for stating in your Funding Statement: “This research was supported by ZOLL Foundation.” Please provide an amended statement that declares all the funding or sources of support (whether external or internal to your organization) received during this study, as detailed online in our guide for authors at http://journals.plos.org/plosone/s/submit-now. Please also include the statement “There was no additional external funding received for this study.” in your updated Funding Statement. Please include your amended Funding Statement within your cover letter. We will change the online submission form on your behalf. 4. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For more information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. In your revised cover letter, please address the following prompts: a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. We will update your Data Availability statement on your behalf to reflect the information you provide. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes ******** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes ****** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ****** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: No ****** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Congratulations to the author for this study. 1. New markers like CT-IGFBP-4 has been identified as predictive novel biomarker of Ischemic Cardiovascular events. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420648/. Please look into this study and discuss this vital biomarker in your discussion. 2. Lately, endothelium, platelets, and coagulation factors as the three vital components has been identified for diagnosing bleeding disorders (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440837/). Please discuss the probable role of the coagulation that measured in cardiac arrest. 3. The manuscript needs major English revision by a native speaker. 4. Authors also needs to give recommendation related to findings of this study. ****** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No ******** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. https://doi.org/10.1371/journal.pone.0279653.r001
Revision 1
7 Nov 2022 Author Response We suggest the Authors to add a paragraph summarizing the main findings focusing on the clinical view. � Thank you for your comments. I added the following sentences in the Discussion Section. Clinically, an increase in D-dimer levels at admission reflects a hypercoagulable state during CA, and a decrease over time reflects systemic fibrinolysis. An increase in the D-dimer level at admission was correlated with time from collapse to ROSC, and the D-dimer level at 24 h was associated with poor neurological outcomes after OHCA, which means that the results of systemic fibrinolysis may be related to the neurological outcome. Although we cannot recommend the use of anticoagulation agents, further studies are needed to suggest an optimal treatment strategy for coagulation abnormalities after CA. 1. New markers like CT-IGFBP-4 has been identified as predictive novel biomarker of Ischemic Cardiovascular events. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9420648/. Please look into this study and discuss this vital biomarker in your discussion. � Thank you for your comments. I added the following sentences in the Discussion Section. When an ischemic cardiovascular event occurs, breakdown of insulin-like growth factor binding protein occurs, increasing the production of CT-IGFBP-4. CT-IGFBP-4 is known to be associated with the early diagnosis and outcomes of ischemic cardiovascular events. In this study, D-dimer at admission was not associated with outcomes after CA. Therefore, it is necessary to study whether CT-IGFBP-4, an early marker, is also useful in PCAS patients treated with TTM. [17] 17. Bhattarai A, Singh Sunar P, Shah S, Chamlagain R, Babu Pokhrel N, Khanal P, et al. CT-IGFBP-4 as a Predictive Novel Biomarker of Ischemic Cardiovascular Events and Mortality: A Systematic Review. Journal of Interventional Cardiology. 2022;2022:1-8. doi: 10.1155/2022/1816504. 2. Lately, endothelium, platelets, and coagulation factors as the three vital components has been identified for diagnosing bleeding disorders (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440837/). Please discuss the probable role of the coagulation that measured in cardiac arrest. � Thank you for your comments. I added the following sentences in the Discussion Section. Nevertheless, coagulofibrinolytic changes in PCAS patients treated with TTM are not fully understood. Endothelium, platelets, and coagulation factors are known as important components in the diagnosis of bleeding disorders and thus should be further studied in PCAS patients treated with TTM. [16] 16. Bhattarai A, Shah S, Bagherieh S, Mirmosayyeb O, Thapa S, Paudel S, et al. Endothelium, Platelets, and Coagulation Factors as the Three Vital Components for Diagnosing Bleeding Disorders: A Simplified Perspective with Clinical Relevance. International Journal of Clinical Practice. 2022;2022:1-10. doi: 10.1155/2022/5369001. 3. The manuscript needs major English revision by a native speaker. � Thank you for your comments. I received English proofreading by a native speaker at American Journal Experts. A proof of English proofreading is attached. 4. Authors also needs to give recommendation related to findings of this study. � Thank you for your comments. I added the following sentences in the Discussion Section. An increase in D-dimer levels at admission reflects a hypercoagulable state during CA, and a decrease in D-dimer levels at 24 hours reflects systemic fibrinolysis. The hypercoagulable state during CA leads to the no-reflow phenomenon, leading to hypoperfusion of vital organs, including the brain. A large-scale randomized study with tissue plasminogen activator during CA showed no evidence of a beneficial effect. [31] However, there have been no studies on the effects of anticoagulant agents in PCAS patients with ROSC. Clinically, an increase in D-dimer levels at admission reflects a hypercoagulable state during CA, and a decrease over time reflects systemic fibrinolysis. An increase in the D-dimer level at admission was correlated with time from collapse to ROSC, and the D-dimer level at 24 h was associated with poor neurological outcomes after OHCA, which means that the results of systemic fibrinolysis may be related to the neurological outcome. Although we cannot recommend the use of anticoagulation agents, further studies are needed to suggest an optimal treatment strategy for coagulation abnormalities after CA. 31. Abu-Laban RB, Christenson JM, Innes GD, Van Beek CA, Wanger KP, McKnight RD, et al. Tissue Plasminogen Activator in Cardiac Arrest with Pulseless Electrical Activity. New Engl J Med. 2002;346(20):1522-8. doi: 10.1056/nejmoa012885. Attachments Attachment Submitted filename: Response to Reviewers.docx https://doi.org/10.1371/journal.pone.0279653.r002
12 Dec 2022 Decision Letter - Chiara Lazzeri, Editor Coagulation measures after cardiac arrest (CMACA) PONE-D-22-13494R1 Dear Dr. Youn, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Chiara Lazzeri Academic Editor PLOS ONE Reviewers' comments: https://doi.org/10.1371/journal.pone.0279653.r003
Formally Accepted
28 Dec 2022 Acceptance Letter - Chiara Lazzeri, Editor PONE-D-22-13494R1 Coagulation measures after cardiac arrest (CMACA) Dear Dr. Youn: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at plosone@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Chiara Lazzeri Academic Editor PLOS ONE https://doi.org/10.1371/journal.pone.0279653.r004

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .